Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mounjaro is a prescription injectable medicine containing tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. It is approved to improve glycemic control in adults and children age 10 and older with type 2 diabetes. Since August 2026, it has also been approved to reduce major cardiovascular events in adults with type 2 diabetes who have high cardiovascular risk.
read more about mounjaro ...Tirzepatide activates GIP and GLP-1 receptors involved in glucose regulation. It increases glucose-dependent insulin secretion, decreases glucagon levels, slows gastric emptying, and affects appetite. These actions improve blood glucose control and can contribute to weight reduction. Its cardiovascular indication is based on clinical outcomes in adults with type 2 diabetes at high risk of cardiovascular events.
Mounjaro is used with diet and exercise in adults and children age 10 and older with type 2 diabetes. It is also indicated to reduce cardiovascular death, nonfatal heart attack, or nonfatal stroke in adults with type 2 diabetes who have high cardiovascular risk. It is not specifically approved under the Mounjaro name for chronic weight management. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 must not receive it.
Mounjaro starts at 2.5 mg by subcutaneous injection once weekly for four weeks, followed by 5 mg once weekly. Further increases occur in 2.5 mg increments after at least four weeks at the current dose when clinically indicated. The maximum dose is 15 mg weekly for adults and 10 mg weekly for patients age 10 through 17. Injections are given in the abdomen, thigh, or upper arm according to product instructions.
Mounjaro carries a boxed warning for thyroid C-cell tumors observed in rats, although the relevance to humans remains unknown. Other serious concerns include pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, allergic reactions, and low blood glucose when combined with insulin or insulin secretagogues. Tirzepatide can also reduce the effectiveness of oral contraceptives around treatment initiation and dose increases.
Mounjaro improves glycemic control in patients age 10 and older with type 2 diabetes and reduces major cardiovascular events in high-risk adults with type 2 diabetes.
The recommended starting dose is 2.5 mg once weekly for four weeks, followed by 5 mg once weekly.
The maximum is 15 mg weekly for adults and 10 mg weekly for pediatric patients age 10 and older.
Yes. Mounjaro carries a boxed warning concerning thyroid C-cell tumors observed in animal studies and is contraindicated in patients with certain thyroid cancer histories.
DailyMed - MOUNJARO (tirzepatide) injection, solution. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0&type=display. Date Accessed October 16, 2026.
FDA Approves Lilly's Mounjaro (tirzepatide) to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes. Eli Lilly and Company. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular. Date Accessed October 16, 2026.
Tirzepatide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK581694/. Date Accessed October 16, 2026.
Tirzepatide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Tirzepatide. Date Accessed October 16, 2026.
Tirzepatide Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622044.html. Date Accessed October 16, 2026.